IMARC Group has recently released a new research study titled "United States Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034", offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

United States Gene Therapy Market Outlook 2034: Opportunities for Biotechnology and Pharmaceutical Stakeholders

The United States gene therapy market size was valued at USD 1,471.0 million in 2025 and is projected to reach USD 3,916.6 million by 2034, registering a compound annual growth rate (CAGR) of 11.15% from 2026 to 2034. This expansion presents significant opportunities for biotechnology developers, pharmaceutical companies, and healthcare providers. Rising genetic disorder prevalence, rapid advances in genetic engineering, strategic collaborations, supportive regulation, and higher R&D investment are shaping United States gene therapy market growth, making it essential for B2B stakeholders to understand the dynamics of this evolving space.

Key Market Statistics at a Glance

Base Year: 2025

Historical Years: 2020–2025

Forecast Period: 2026–2034

Market Size (2025): USD 1,471.0 Million

Projected Size (2034): USD 3,916.6 Million

Growth Rate: CAGR of 11.15%

Explore Growth Opportunities in the United States Gene Therapy Market Grab Your Sample Report for Evaluation: https://www.imarcgroup.com/united-states-gene-therapy-market/requestsample

How Genetic Engineering Advances Are Transforming the United States Gene Therapy Market

Recent progress in genetic engineering and biotechnology is reshaping the therapeutic landscape. Gene-editing tools such as CRISPR/Cas9 make it easier to identify and correct mutations linked to disease, while academic and biotech R&D spending is accelerating clinical timelines. These developments define the key United States gene therapy market trends that developers and investors are tracking closely.

Key Technology Trends:

•        Gene Editing Platforms: In October 2023, the National Institutes of Health awarded Yale School of Medicine almost USD 40 million to develop a phase 2 CRISPR-based gene therapy platform targeting genetic brain diseases such as Angelman syndrome.

•        Direct-to-Brain Delivery: In November 2024, the U.S. FDA granted accelerated approval to PTC Therapeutics’ gene therapy for AADC deficiency, the first gene therapy approved in the country that is administered directly to the brain.

•        AAV Vector Innovation: In April 2024, the FDA approved Pfizer’s BEQVEZ, an adeno-associated virus vector-based therapy for adults with moderate to severe hemophilia B.

United States Gene Therapy Market: Key Growth Drivers and Strategic Insights for Businesses

Several factors are fueling the expansion of gene therapy in the country. Strong United States gene therapy market demand is being created by a growing patient pool, a favorable regulatory environment, and an expanding care delivery network.

Key Growth Drivers:

1.      Rising Prevalence of Genetic Disorders and Cancer: Around 2,001,140 new cancer cases were expected in the United States in 2024, with 611,720 deaths. The population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase, further raising the need for advanced treatments.

2.      Supportive Regulatory Frameworks: The FDA has designated more than 1,000 medicines as orphan drugs, and over 100 treatments had received Regenerative Medicine Advanced Therapy (RMAT) designation as of 2023. More than 20 gene treatments, including Zolgensma and Hemgenix, have been cleared since 2017.

3.      Strategic Collaborations and Partnerships: In January 2023, Spark Therapeutics and Neurochase signed an exclusive agreement to pair Neurochase’s direct-delivery technology with Spark’s AAV platform for rare central nervous system diseases.

4.      Expanding Healthcare Infrastructure: IQVIA counted 114 gene therapy trials started in 2023, with 88 (77%) industry-sponsored, while more than 50 certified centers now deliver gene therapies nationwide. Novartis secured coverage for Zolgensma for about 97% of commercially insured patients and 86% of Medicaid patients.

Strategic Insights:

•        Prioritize Oncology and Rare Disease Pipelines: These applications offer the clearest clinical need and regulatory support through orphan drug and RMAT pathways.

•        Build Collaborative Networks: Partnerships among biotech firms, pharma companies, and universities pool funding and expertise, and companies that secure early reimbursement and regulatory designations are better placed to capture a larger United States gene therapy market share.

•        Track Regional Innovation Hubs: The Northeast and West concentrate research institutions, biotech clusters, and venture capital, which supports United States gene therapy market growth through faster commercialization.

Why Stakeholders Are Investing in Gene Therapy Solutions Across the United States

Companies, investors, and research institutions increasingly view gene therapy as a long-term growth area. A detailed United States gene therapy market analysis helps these stakeholders weigh opportunity against clinical, regulatory, and reimbursement risk.

Reasons for Investment:

•        Treatment Potential: Gene therapy offers a route to long-term solutions for conditions such as hemophilia, spinal muscular atrophy, and cystic fibrosis that were previously considered incurable.

•        Regulatory Acceleration: Orphan drug and RMAT designations speed up development and approval, shortening the path to market.

•        Improving Access: Broader insurance coverage and a growing network of certified treatment centers make therapies easier for patients to obtain, sustaining United States gene therapy market demand.

United States Gene Therapy Market Segmentation:

IMARC Group’s United States gene therapy market analysis covers the key United States gene therapy market trends within each segment, with forecasts at the country and regional levels from 2026 to 2034.

Gene Type Insights:

•        Antigen

•        Cytokine

•        Tumor Suppressor

•        Suicide Gene

•        Deficiency

•        Growth Factors

•        Receptors

•        Others

Vector Type Insights:

•        Viral Vector

◦         Adenoviruses

◦         Lentiviruses

◦         Retroviruses

◦         Adeno-Associated Virus

◦         Herpes Simplex Virus

◦         Poxvirus

◦         Vaccinia Virus

◦         Others

•        Non-Viral Techniques

◦         Naked and Plasmid Vectors

◦         Gene Gun

◦         Electroporation

◦         Lipofection

◦         Others

Delivery Method Insights:

•        In-Vivo Gene Therapy

•        Ex-Vivo Gene Therapy

Application Insights:

•        Oncological Disorders

•        Rare Diseases

•        Cardiovascular Diseases

•        Neurological Disorders

•        Infectious Disease

•        Others

Regional Insights:

•        Northeast

•        Midwest

•        South

•        West

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=11240&flag=C

Leading Companies in the United States Gene Therapy Market

Competition is intensifying as developers pursue regulatory approvals, clinical progress, and favorable reimbursement agreements, all of which influence United States gene therapy market share across indications. Companies active in the space include:

•        Novartis: Developer of Zolgensma, a gene therapy for spinal muscular atrophy that has secured broad commercial and Medicaid coverage.

•        Pfizer Inc.: Markets BEQVEZ, an AAV vector-based gene therapy approved by the FDA in April 2024 for adults with moderate to severe hemophilia B.

•        PTC Therapeutics, Inc.: Gained FDA accelerated approval in November 2024 for a gene therapy for AADC deficiency, delivered directly to the brain.

•        Spark Therapeutics: Develops AAV-based gene therapies and signed an exclusive agreement with Neurochase in January 2023 on direct delivery for central nervous system diseases.

Key Takeaways for Stakeholders

The United States gene therapy market size is on track to more than double between 2025 and 2034, reflecting sustained United States gene therapy market growth driven by innovation and policy support. Stakeholders should monitor United States gene therapy market trends in gene editing and vector technology, track United States gene therapy market demand across oncology, rare disease, and neurology applications, and rely on United States gene therapy market analysis to benchmark United States gene therapy market share among leading developers.

Author IMARC Group

IMARC Group is a leading global management consulting firm providing comprehensive market research, feasibility studies, and strategic advisory services. The firm supports organizations worldwide in identifying growth opportunities, mitigating risks, and making informed business decisions across industries.

Contact Us

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302